img

Global Postmenopausal Vaginal Atrophy Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Postmenopausal Vaginal Atrophy Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Postmenopausal vaginal atrophy (PVA) is the type of condition of vaginal wall thinning the reduced level of estrogen causes that. The changes in the genitourinary tract arising from a hypoestrogenic state includes decreased vaginal vascularization, reduced vaginal lubrication, thinning of the vaginal epithelium. The pH level continuously increases and loss of lactobacilli microflora allows opportunistic colonization by pathogenic bacteria can produce infection.
Postmenopausal Vaginal Atrophy Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Postmenopausal Vaginal Atrophy Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Online Pharmacy and Hospital Pharmacy are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Postmenopausal Vaginal Atrophy Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Postmenopausal Vaginal Atrophy Drugs key manufacturers include Pfizer Inc, Mylan NV, Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc, Melinta Therapeutics, Inc, Bristol-Myers Squibb Company and GSK plc, etc. Pfizer Inc, Mylan NV, Novartis AG are top 3 players and held % sales share in total in 2022.
Postmenopausal Vaginal Atrophy Drugs can be divided into Topical Estrogen, Oral Estrogen and Other,, etc. Topical Estrogen is the mainstream product in the market, accounting for % sales share globally in 2022.
Postmenopausal Vaginal Atrophy Drugs is widely used in various fields, such as Online Pharmacy and Hospital Pharmacy, etc. Online Pharmacy provides greatest supports to the Postmenopausal Vaginal Atrophy Drugs industry development. In 2022, global % sales of Postmenopausal Vaginal Atrophy Drugs went into Online Pharmacy filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Postmenopausal Vaginal Atrophy Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Pfizer Inc
Mylan NV
Novartis AG
Hikma Pharmaceuticals plc
Aurobindo Pharma
AbbVie Inc
Melinta Therapeutics, Inc
Bristol-Myers Squibb Company
GSK plc
Bayer AG
Lupin
Perrigo Company plc
Bionovo, Inc
TherapeuticsMD, Inc
Endoceutics, Inc
Segment by Type
Topical Estrogen
Oral Estrogen
Other

Segment by Application


Online Pharmacy
Hospital Pharmacy

Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Postmenopausal Vaginal Atrophy Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Postmenopausal Vaginal Atrophy Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Postmenopausal Vaginal Atrophy Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Postmenopausal Vaginal Atrophy Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Postmenopausal Vaginal Atrophy Drugs introduction, etc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Postmenopausal Vaginal Atrophy Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Postmenopausal Vaginal Atrophy Drugs Market Overview
1.1 Postmenopausal Vaginal Atrophy Drugs Product Overview
1.2 Postmenopausal Vaginal Atrophy Drugs Market Segment by Type
1.2.1 Topical Estrogen
1.2.2 Oral Estrogen
1.2.3 Other
1.3 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Type
1.3.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Overview by Type (2018-2034)
1.3.2 Global Postmenopausal Vaginal Atrophy Drugs Historic Market Size Review by Type (2018-2024)
1.3.3 Global Postmenopausal Vaginal Atrophy Drugs Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2018-2024)
1.4.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2018-2024)
2 Global Postmenopausal Vaginal Atrophy Drugs Market Competition by Company
2.1 Global Top Players by Postmenopausal Vaginal Atrophy Drugs Sales (2018-2024)
2.2 Global Top Players by Postmenopausal Vaginal Atrophy Drugs Revenue (2018-2024)
2.3 Global Top Players by Postmenopausal Vaginal Atrophy Drugs Price (2018-2024)
2.4 Global Top Manufacturers Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Postmenopausal Vaginal Atrophy Drugs Market Competitive Situation and Trends
2.5.1 Postmenopausal Vaginal Atrophy Drugs Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
2.8 Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Postmenopausal Vaginal Atrophy Drugs Status and Outlook by Region
3.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Postmenopausal Vaginal Atrophy Drugs Historic Market Size by Region
3.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Region (2018-2024)
3.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales in Value by Region (2018-2024)
3.2.3 Global Postmenopausal Vaginal Atrophy Drugs Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Postmenopausal Vaginal Atrophy Drugs Forecasted Market Size by Region
3.3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Region (2024-2034)
3.3.2 Global Postmenopausal Vaginal Atrophy Drugs Sales in Value by Region (2024-2034)
3.3.3 Global Postmenopausal Vaginal Atrophy Drugs Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Postmenopausal Vaginal Atrophy Drugs by Application
4.1 Postmenopausal Vaginal Atrophy Drugs Market Segment by Application
4.1.1 Online Pharmacy
4.1.2 Hospital Pharmacy
4.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Application
4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Overview by Application (2018-2034)
4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Historic Market Size Review by Application (2018-2024)
4.2.3 Global Postmenopausal Vaginal Atrophy Drugs Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application (2018-2024)
4.3.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application (2018-2024)
5 North America Postmenopausal Vaginal Atrophy Drugs by Country
5.1 North America Postmenopausal Vaginal Atrophy Drugs Historic Market Size by Country
5.1.1 North America Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Country (2018-2024)
5.1.3 North America Postmenopausal Vaginal Atrophy Drugs Sales in Value by Country (2018-2024)
5.2 North America Postmenopausal Vaginal Atrophy Drugs Forecasted Market Size by Country
5.2.1 North America Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Country (2024-2034)
5.2.2 North America Postmenopausal Vaginal Atrophy Drugs Sales in Value by Country (2024-2034)
6 Europe Postmenopausal Vaginal Atrophy Drugs by Country
6.1 Europe Postmenopausal Vaginal Atrophy Drugs Historic Market Size by Country
6.1.1 Europe Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Country (2018-2024)
6.1.3 Europe Postmenopausal Vaginal Atrophy Drugs Sales in Value by Country (2018-2024)
6.2 Europe Postmenopausal Vaginal Atrophy Drugs Forecasted Market Size by Country
6.2.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Country (2024-2034)
6.2.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales in Value by Country (2024-2034)
7 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs by Region
7.1 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales in Value by Region (2024-2034)
8 Latin America Postmenopausal Vaginal Atrophy Drugs by Country
8.1 Latin America Postmenopausal Vaginal Atrophy Drugs Historic Market Size by Country
8.1.1 Latin America Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Country (2018-2024)
8.1.3 Latin America Postmenopausal Vaginal Atrophy Drugs Sales in Value by Country (2018-2024)
8.2 Latin America Postmenopausal Vaginal Atrophy Drugs Forecasted Market Size by Country
8.2.1 Latin America Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Country (2024-2034)
8.2.2 Latin America Postmenopausal Vaginal Atrophy Drugs Sales in Value by Country (2024-2034)
9 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs by Country
9.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Pfizer Inc
10.1.1 Pfizer Inc Company Information
10.1.2 Pfizer Inc Introduction and Business Overview
10.1.3 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Products Offered
10.1.5 Pfizer Inc Recent Development
10.2 Mylan NV
10.2.1 Mylan NV Company Information
10.2.2 Mylan NV Introduction and Business Overview
10.2.3 Mylan NV Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Mylan NV Postmenopausal Vaginal Atrophy Drugs Products Offered
10.2.5 Mylan NV Recent Development
10.3 Novartis AG
10.3.1 Novartis AG Company Information
10.3.2 Novartis AG Introduction and Business Overview
10.3.3 Novartis AG Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Novartis AG Postmenopausal Vaginal Atrophy Drugs Products Offered
10.3.5 Novartis AG Recent Development
10.4 Hikma Pharmaceuticals plc
10.4.1 Hikma Pharmaceuticals plc Company Information
10.4.2 Hikma Pharmaceuticals plc Introduction and Business Overview
10.4.3 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Products Offered
10.4.5 Hikma Pharmaceuticals plc Recent Development
10.5 Aurobindo Pharma
10.5.1 Aurobindo Pharma Company Information
10.5.2 Aurobindo Pharma Introduction and Business Overview
10.5.3 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Products Offered
10.5.5 Aurobindo Pharma Recent Development
10.6 AbbVie Inc
10.6.1 AbbVie Inc Company Information
10.6.2 AbbVie Inc Introduction and Business Overview
10.6.3 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2024)
10.6.4 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Products Offered
10.6.5 AbbVie Inc Recent Development
10.7 Melinta Therapeutics, Inc
10.7.1 Melinta Therapeutics, Inc Company Information
10.7.2 Melinta Therapeutics, Inc Introduction and Business Overview
10.7.3 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Products Offered
10.7.5 Melinta Therapeutics, Inc Recent Development
10.8 Bristol-Myers Squibb Company
10.8.1 Bristol-Myers Squibb Company Company Information
10.8.2 Bristol-Myers Squibb Company Introduction and Business Overview
10.8.3 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Products Offered
10.8.5 Bristol-Myers Squibb Company Recent Development
10.9 GSK plc
10.9.1 GSK plc Company Information
10.9.2 GSK plc Introduction and Business Overview
10.9.3 GSK plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2024)
10.9.4 GSK plc Postmenopausal Vaginal Atrophy Drugs Products Offered
10.9.5 GSK plc Recent Development
10.10 Bayer AG
10.10.1 Bayer AG Company Information
10.10.2 Bayer AG Introduction and Business Overview
10.10.3 Bayer AG Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Bayer AG Postmenopausal Vaginal Atrophy Drugs Products Offered
10.10.5 Bayer AG Recent Development
10.11 Lupin
10.11.1 Lupin Company Information
10.11.2 Lupin Introduction and Business Overview
10.11.3 Lupin Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Lupin Postmenopausal Vaginal Atrophy Drugs Products Offered
10.11.5 Lupin Recent Development
10.12 Perrigo Company plc
10.12.1 Perrigo Company plc Company Information
10.12.2 Perrigo Company plc Introduction and Business Overview
10.12.3 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Products Offered
10.12.5 Perrigo Company plc Recent Development
10.13 Bionovo, Inc
10.13.1 Bionovo, Inc Company Information
10.13.2 Bionovo, Inc Introduction and Business Overview
10.13.3 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Products Offered
10.13.5 Bionovo, Inc Recent Development
10.14 TherapeuticsMD, Inc
10.14.1 TherapeuticsMD, Inc Company Information
10.14.2 TherapeuticsMD, Inc Introduction and Business Overview
10.14.3 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2024)
10.14.4 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Products Offered
10.14.5 TherapeuticsMD, Inc Recent Development
10.15 Endoceutics, Inc
10.15.1 Endoceutics, Inc Company Information
10.15.2 Endoceutics, Inc Introduction and Business Overview
10.15.3 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2018-2024)
10.15.4 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Products Offered
10.15.5 Endoceutics, Inc Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Postmenopausal Vaginal Atrophy Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Postmenopausal Vaginal Atrophy Drugs Industrial Chain Analysis
11.4 Postmenopausal Vaginal Atrophy Drugs Market Dynamics
11.4.1 Postmenopausal Vaginal Atrophy Drugs Industry Trends
11.4.2 Postmenopausal Vaginal Atrophy Drugs Market Drivers
11.4.3 Postmenopausal Vaginal Atrophy Drugs Market Challenges
11.4.4 Postmenopausal Vaginal Atrophy Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Postmenopausal Vaginal Atrophy Drugs Distributors
12.3 Postmenopausal Vaginal Atrophy Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Topical Estrogen
Table 2. Major Company of Oral Estrogen
Table 3. Major Company of Other
Table 4. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2018-2024) & (K Units)
Table 6. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type (2018-2024)
Table 7. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2018-2024) & (US& Million)
Table 8. Global Postmenopausal Vaginal Atrophy Drugs Market Share in Value by Type (2018-2024)
Table 9. Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2018-2024) & (US$/Unit)
Table 10. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2024-2034) & (K Units)
Table 11. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type (2024-2034)
Table 12. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2024-2034) & (US$ Million)
Table 13. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type (2024-2034)
Table 14. Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2024-2034) & (US$/Unit)
Table 15. North America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2018-2024) & (K Units)
Table 16. North America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2018-2024) & (US$ Million)
Table 17. Europe Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2018-2024)
Table 18. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Type (2018-2024) & (US$ Million)
Table 19. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2018-2024)
Table 20. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Type (2018-2024) & (US$ Million)
Table 21. Latin America Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2018-2024)
Table 22. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2018-2024) & (US$ Million)
Table 23. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2018-2024)
Table 24. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Type (2018-2024) & (US$ Million)
Table 25. Global Postmenopausal Vaginal Atrophy Drugs Sales by Company (2018-2024) & (K Units)
Table 26. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Company (2018-2024)
Table 27. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 28. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Company (2018-2024)
Table 29. Global Market Postmenopausal Vaginal Atrophy Drugs Price by Company (2018-2024) & (US$/Unit)
Table 30. Global Postmenopausal Vaginal Atrophy Drugs Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 31. Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 32. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2022)
Table 33. Date of Key Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
Table 34. Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Postmenopausal Vaginal Atrophy Drugs Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 37. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2018-2024) & (K Units)
Table 38. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Region (2018-2024)
Table 39. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2018-2024) & (US$ Million)
Table 40. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Region (2018-2024)
Table 41. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 42. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2024-2034) & (K Units)
Table 43. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Region (2024-2034)
Table 44. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2024-2034) & (US$ Million)
Table 45. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Region (2024-2034)
Table 46. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2034)
Table 47. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 48. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2018-2024) & (K Units)
Table 49. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application (2018-2024)
Table 50. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2018-2024) & (US$ Million)
Table 51. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application (2018-2024)
Table 52. Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2018-2024) & (US$/Unit)
Table 53. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2024-2034) & (K Units)
Table 54. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application (2024-2034)
Table 55. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2024-2034) & (US$ Million)
Table 56. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application (2024-2034)
Table 57. Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2024-2034) & (US$/Unit)
Table 58. North America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2018-2024) (K Units)
Table 59. North America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2018-2024) & (US$ Million)
Table 60. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Application (2018-2024) (K Units)
Table 61. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Application (2018-2024) & (US$ Million)
Table 62. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Application (2018-2024) (K Units)
Table 63. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Application (2018-2024) & (US$ Million)
Table 64. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2018-2024) (K Units)
Table 65. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2018-2024) & (US$ Million)
Table 66. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Application (2018-2024) (K Units)
Table 67. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Application (2018-2024) & (US$ Million)
Table 68. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2018-2024) & (K Units)
Table 69. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Country (2018-2024)
Table 70. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2018-2024) & (US$ Million)
Table 71. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Country (2018-2024)
Table 72. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2024-2034) & (K Units)
Table 73. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Country (2024-2034)
Table 74. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2024-2034) & (US$ Million)
Table 75. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Country (2024-2034)
Table 76. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2018-2024) & (K Units)
Table 77. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Country (2018-2024)
Table 78. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2018-2024) & (US$ Million)
Table 79. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Country (2018-2024)
Table 80. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2024-2034) & (K Units)
Table 81. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Country (2024-2034)
Table 82. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2024-2034) & (US$ Million)
Table 83. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Country (2024-2034)
Table 84. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2018-2024) & (K Units)
Table 85. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Region (2018-2024)
Table 86. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2018-2024) & (US$ Million)
Table 87. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Region (2018-2024)
Table 88. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2024-2034) & (K Units)
Table 89. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Region (2024-2034)
Table 90. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2024-2034) & (US$ Million)
Table 91. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Region (2024-2034)
Table 92. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2018-2024) & (K Units)
Table 93. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Country (2018-2024)
Table 94. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2018-2024) & (US$ Million)
Table 95. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Country (2018-2024)
Table 96. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2024-2034) & (K Units)
Table 97. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Country (2024-2034)
Table 98. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2024-2034) & (US$ Million)
Table 99. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Country (2024-2034)
Table 100. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2018-2024) & (K Units)
Table 101. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Country (2018-2024)
Table 102. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2018-2024) & (US$ Million)
Table 103. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Country (2018-2024)
Table 104. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2024-2034) & (K Units)
Table 105. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Country (2024-2034)
Table 106. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2024-2034) & (US$ Million)
Table 107. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Country (2024-2034)
Table 108. Pfizer Inc Company Information
Table 109. Pfizer Inc Introduction and Business Overview
Table 110. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 111. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product
Table 112. Pfizer Inc Recent Development
Table 113. Mylan NV Company Information
Table 114. Mylan NV Introduction and Business Overview
Table 115. Mylan NV Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 116. Mylan NV Postmenopausal Vaginal Atrophy Drugs Product
Table 117. Mylan NV Recent Development
Table 118. Novartis AG Company Information
Table 119. Novartis AG Introduction and Business Overview
Table 120. Novartis AG Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 121. Novartis AG Postmenopausal Vaginal Atrophy Drugs Product
Table 122. Novartis AG Recent Development
Table 123. Hikma Pharmaceuticals plc Company Information
Table 124. Hikma Pharmaceuticals plc Introduction and Business Overview
Table 125. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 126. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Product
Table 127. Hikma Pharmaceuticals plc Recent Development
Table 128. Aurobindo Pharma Company Information
Table 129. Aurobindo Pharma Introduction and Business Overview
Table 130. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 131. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Product
Table 132. Aurobindo Pharma Recent Development
Table 133. AbbVie Inc Company Information
Table 134. AbbVie Inc Introduction and Business Overview
Table 135. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 136. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Product
Table 137. AbbVie Inc Recent Development
Table 138. Melinta Therapeutics, Inc Company Information
Table 139. Melinta Therapeutics, Inc Introduction and Business Overview
Table 140. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 141. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Product
Table 142. Melinta Therapeutics, Inc Recent Development
Table 143. Bristol-Myers Squibb Company Company Information
Table 144. Bristol-Myers Squibb Company Introduction and Business Overview
Table 145. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 146. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Product
Table 147. Bristol-Myers Squibb Company Recent Development
Table 148. GSK plc Company Information
Table 149. GSK plc Introduction and Business Overview
Table 150. GSK plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 151. GSK plc Postmenopausal Vaginal Atrophy Drugs Product
Table 152. GSK plc Recent Development
Table 153. Bayer AG Company Information
Table 154. Bayer AG Introduction and Business Overview
Table 155. Bayer AG Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 156. Bayer AG Postmenopausal Vaginal Atrophy Drugs Product
Table 157. Bayer AG Recent Development
Table 158. Lupin Company Information
Table 159. Lupin Introduction and Business Overview
Table 160. Lupin Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 161. Lupin Postmenopausal Vaginal Atrophy Drugs Product
Table 162. Lupin Recent Development
Table 163. Perrigo Company plc Company Information
Table 164. Perrigo Company plc Introduction and Business Overview
Table 165. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 166. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Product
Table 167. Perrigo Company plc Recent Development
Table 168. Bionovo, Inc Company Information
Table 169. Bionovo, Inc Introduction and Business Overview
Table 170. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 171. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Product
Table 172. Bionovo, Inc Recent Development
Table 173. TherapeuticsMD, Inc Company Information
Table 174. TherapeuticsMD, Inc Introduction and Business Overview
Table 175. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 176. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Product
Table 177. TherapeuticsMD, Inc Recent Development
Table 178. Endoceutics, Inc Company Information
Table 179. Endoceutics, Inc Introduction and Business Overview
Table 180. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 181. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Product
Table 182. Endoceutics, Inc Recent Development
Table 183. Key Raw Materials Lists
Table 184. Raw Materials Key Suppliers Lists
Table 185. Postmenopausal Vaginal Atrophy Drugs Market Trends
Table 186. Postmenopausal Vaginal Atrophy Drugs Market Drivers
Table 187. Postmenopausal Vaginal Atrophy Drugs Market Challenges
Table 188. Postmenopausal Vaginal Atrophy Drugs Market Restraints
Table 189. Postmenopausal Vaginal Atrophy Drugs Distributors List
Table 190. Postmenopausal Vaginal Atrophy Drugs Downstream Customers
Table 191. Research Programs/Design for This Report
Table 192. Key Data Information from Secondary Sources
Table 193. Key Data Information from Primary Sources
List of Figures
Figure 1. Postmenopausal Vaginal Atrophy Drugs Product Picture
Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Postmenopausal Vaginal Atrophy Drugs Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Postmenopausal Vaginal Atrophy Drugs Sales Status and Outlook (2018-2034) & (K Units)
Figure 5. Product Picture of Topical Estrogen
Figure 6. Global Topical Estrogen Sales YoY Growth (2018-2034) & (K Units)
Figure 7. Product Picture of Oral Estrogen
Figure 8. Global Oral Estrogen Sales YoY Growth (2018-2034) & (K Units)
Figure 9. Product Picture of Other
Figure 10. Global Other Sales YoY Growth (2018-2034) & (K Units)
Figure 11. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2018-2034) & (US$ Million)
Figure 12. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2022 & 2034
Figure 13. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type in 2022
Figure 14. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type in 2022
Figure 15. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type in 2022
Figure 16. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type in 2022
Figure 17. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type in 2022
Figure 18. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type in 2022
Figure 19. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type in 2022
Figure 20. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type in 2022
Figure 21. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type in 2022
Figure 22. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type in 2022
Figure 23. The 5 and 10 Largest Manufacturers in the World: Market Share by Postmenopausal Vaginal Atrophy Drugs Sales in 2022
Figure 24. The 5 and 10 Largest Manufacturers in the World: Market Share by Postmenopausal Vaginal Atrophy Drugs Revenue in 2022
Figure 25. Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 26. Product Picture of Online Pharmacy
Figure 27. Global Online Pharmacy Sales YoY Growth (2018-2034) & (K Units)
Figure 28. Product Picture of Hospital Pharmacy
Figure 29. Global Hospital Pharmacy Sales YoY Growth (2018-2034) & (K Units)
Figure 30. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2018-2034) & (US$ Million)
Figure 31. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application in 2022 & 2034
Figure 32. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application in 2022
Figure 33. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application in 2022
Figure 34. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application in 2022
Figure 35. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application in 2022
Figure 36. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application in 2022
Figure 37. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application in 2022
Figure 38. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application in 2022
Figure 39. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application in 2022
Figure 40. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application in 2022
Figure 41. Key Raw Materials Price
Figure 42. Postmenopausal Vaginal Atrophy Drugs Manufacturing Cost Structure
Figure 43. Postmenopausal Vaginal Atrophy Drugs Industrial Chain Analysis
Figure 44. Channels of Distribution
Figure 45. Distributors Profiles
Figure 46. Bottom-up and Top-down Approaches for This Report
Figure 47. Data Triangulation
Figure 48. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries